The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version ...
IQVIA reported annual sales for the twelve months ending September 2024 of $4.3 billion for the brand and generic market for this product. About Elite Pharmaceuticals, Inc.
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...